Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly’s Ceclor

Executive Summary

Lilly oral cephalosporin product is showing "sales growth in the mid-teens" percentage range in 1990, Exec VP and Pharmaceutical Division President Eugene Step told Mabon Nugent research conference Dec. 5. Eleven-year old oral cephalosporin cefaclor loses patent exclusivity in mid-1992, but Step said generic competitors "may be in for a bit of a surprise" because cefaclor's "complex production process" may keep generic companies from seeking to market product. He noted that, outside the U.S. where no patent protection exists, Lilly knows of no generic Ceclor on the market or in development. Lilly's H[2] antagonist Axid (nizatidine) and Humatrope (somatropin) human growth hormone are both growing in sales "well above 50% this year," Step said, with Humatrope expected to top $100 mil. in sales, the eighth Lilly drug to exceed that milestone. Carbacephem broad spectrum antibiotic loracarbef NDA is "on track at FDA," he noted.

You may also be interested in...



US FDA And NIST Form Partnership To Boost Advanced Manufacturing Techniques

The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.

Medtronic Looks To Adaptive DBS To Advance Treatment Of Parkinson’s Disease

Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.

Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint

The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel